Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vicadrostat - Boehringer Ingelheim

Next Previous
X
Search
Drug Profile

Vicadrostat - Boehringer Ingelheim

Alternative Names: BI-690517; C 14

Latest Information Update: 23 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Class Urologics
  • Mechanism of Action Aldosterone synthase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Heart failure; Renal failure
  • No development reported Diabetic nephropathies

Most Recent Events

  • 18 Oct 2024 Boehringer Ingelheim plans a phase I pharmacokinetics trial (In volunteers) (PO), in November 2024 (NCT06647810)
  • 30 Aug 2024 Efficacy data from a phase II trial in Renal failure presented at the Annual Congress of the European Society of Cardiology (ESC-Card-2024)
  • 30 Aug 2024 Phase-III clinical trials in Renal failure (Combination therapy) in United Kingdom (PO) (NCT06531824)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top